Rezolute to Host Virtual Investor Event on Ersodetug Development Program

Core Insights - Rezolute, Inc. is hosting a virtual investor event on November 10, 2025, to discuss the market opportunity and clinical development of its drug, ersodetug, which is in Phase 3 studies for congenital and tumor hyperinsulinism [1][2] Company Overview - Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI) [5] - The company's antibody therapy, ersodetug, aims to treat all forms of HI and has demonstrated significant benefits in clinical trials and real-world applications [5] Clinical Development - The event will feature discussions on the ongoing clinical development programs, including the Phase 3 sunRIZE study for congenital HI, with topline results expected in December 2025, and the Phase 3 upLIFT study for tumor HI [2] - Ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor, reducing receptor over-activation and improving hypoglycemia in patients with HI [4] Market Opportunity - The Chief Commercial Officer will discuss the anticipated commercial opportunities for ersodetug as a treatment for both congenital and tumor HI [2] - The event will also include insights from leading hyperinsulinism experts regarding the unmet medical needs and current treatment landscape for these conditions [2]